Galectin Therapeutics (GALT) has a clinical trial milestone to watch for this month, which is related to its lead drug candidate, Belapectin, in metabolic dysfunction-associated steatohepatitis, or MASH, with cirrhosis.
Belapectin is a carbohydrate-based drug that inhibits galectin-3, a protein involved in fibrosis and inflammation in chronic liver diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com